Roger Li
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
Roger Li
Jun 19, 2024, 07:50 |
Blog
Roger Li: The final results of the CORE001 trial are out now in Nature Medicine
Patrick Hwu shared a post by Roger Li, Urologic oncologist at Moffitt Cancer Center, on…
Jun 13, 2024, 07:21 |
Blog
Sumanta K. Pal: Looking forward to joining Roger Li and Vikram M. Narayan for a quick ASCO24 update
Sumanta K. Pal shared a post on X: "Looking forward to joining Roger Li and Vikram…
Jun 8, 2024, 17:22 |
Blog
Roger Li: Final results of CORE001 trial at Nature Medicine
Roger Li, Urologic oncologist at Moffitt Cancer Center, shared on X/Twitter: "Final results of CORE001 trial…
Dec 30, 2023, 17:58 |
Opinion
Laura Bukavina: Let's dive into the topic of non-muscle-invasive bladder cancer
Laura Bukavina, Urologic Oncologist at University Hospitals Cleveland Medical Center, shared a post on X/Twitter:…
Aug 9, 2023, 06:42 |
Blog
Great collaboration between Global Society of Rare GU tumors and International Bladder Cancer Group - Karima Oualla
Honored to be part of the fantastic Bladder Cancer Advocacy Network Think Tank, that took…
All:
5
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube